Pegvisomant
| Pegvisomant | ||
|---|---|---|
| Mass / length primary structure | 22.1 kDa | |
| Identifier | ||
| External IDs |
|
|
| Drug information | ||
| ATC code | H01 AX01 | |
| DrugBank | DB00082 | |
| Drug class | Somatotropin - Antagonist | |
Pegvisomant (trade name: Somavert ® , manufacturer: Pfizer ) is a medicinal substance . It acts as an antagonist of the receptor for somatotropin , a growth hormone , and is produced recombinantly . Pegvisomant is commercially available as a powder for the preparation of a solution for injection and is used to treat acromegaly and is injected into the subcutaneous tissue.
Mechanism of action
Acromegaly is a hormonal disorder that from an increased secretion of the growth hormone somatotropin and the hormone IGF -1 (insulin-like growth factor-1, English insulin-like growth factor-1 ) results and in an overgrowth of bone and soft tissue expresses. As a receptor antagonist, pegvisomant binds to growth hormone receptors on the cell surface, where it blocks the binding of the somatotropin and thus its effect. As a result, the serum level of IGF-1 also falls.
unwanted effects
The side effects of pegvisomant may include: a. Reactions at the injection site, peripheral edema (swelling of the limbs), chest pain, paresthesia (abnormal sensations such as tingling, etc.), disturbances in blood sugar levels, nausea and inflammation of the liver ( hepatitis ).
Individual evidence
- ↑ Karavitaki N. et al .: pegvisomant: a new treatment modality for acromegaly Hormones (Athens). January - March 2004, Volume 3, No. 1, pp. 27-36. PMID 16982575 Full Text .
- ↑ Feenstra J. et al .: Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant Eur J Endocrinol., June 2006, Volume 154, No. 6, p. 805–806 PMID 16728538 Full Text (PDF; 57 kB) ( Page no longer available , search in web archives ) Info: The link was automatically marked as defective. Please check the link according to the instructions and then remove this notice. .
- ↑ HCI Solutions AG: Somavert® - compendium.ch. In: compendium.ch. Retrieved April 1, 2016 .
Web links
- Summary of Product Characteristics (PDF), published by the European Medicines Agency (424 kB)
- Scientific Discussion of Somavert (PDF; 336 kB), published by the European Medicines Agency
